30 studies found for:    Recurrent GBM | Immunotherapy
Show Display Options
Rank Status Study
1 Active, not recruiting Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme
Condition: Recurrent Central Nervous System Neoplasm
Intervention: Biological: BTSC mRNA-loaded DCs
2 Recruiting Phase 2 Study of MEDI4736 in Patients With Glioblastoma
Condition: Glioblastoma
Interventions: Drug: MEDI4736;   Radiation: Radiotherapy;   Biological: Bevacizumab
3 Not yet recruiting A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Conditions: Glioblastoma;   Astrocytoma, Grade IV
Intervention: Drug: EGFR(V)-EDV-Dox
4 Recruiting DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
Condition: Glioblastoma or Gliosarcoma
Interventions: Drug: Single intratumoral injection of DNX-2401;   Drug: Interferon-gamma
5 Recruiting Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma
Conditions: Glioblastoma;   Glioblastoma Multiforme;   Glioma;   Astrocytoma;   Brain Tumor
Interventions: Biological: Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy;   Biological: Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
6 Completed Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
Conditions: Anaplastic Astrocytoma;   Anaplastic Ependymoma;   Anaplastic Meningioma;   Anaplastic Oligodendroglioma;   Brain Stem Glioma;   Ependymoblastoma;   Giant Cell Glioblastoma;   Glioblastoma;   Gliosarcoma;   Grade III Meningioma;   Meningeal Hemangiopericytoma;   Mixed Glioma;   Pineal Gland Astrocytoma;   Brain Tumor
Interventions: Biological: therapeutic allogeneic lymphocytes;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography
7 Withdrawn Cellular Immunotherapy Study for Brain Cancer
Conditions: Gliomas;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Mixed Glioma;   Glioblastoma Multiforme;   Malignant Meningioma
Intervention: Drug: alloreactive CTL
8 Recruiting Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Conditions: Adult Brain Glioblastoma;   Glioblastoma Multiforme
Interventions: Biological: SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose);   Drug: Bevacizumab
9 Recruiting A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma
Condition: Glioblastoma Multiforme
Intervention: Biological: ICT-121 DC vaccine
10 Completed A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
Condition: Glioblastoma
Interventions: Drug: Vorinostat;   Drug: Bevacizumab;   Drug: Irinotecan
11 Recruiting Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma
Condition: Glioblastoma
Interventions: Radiation: Stereotactic Radiosurgery;   Drug: Nivolumab;   Drug: Valproate
12 Active, not recruiting Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
Condition: Brain Tumor, Recurrent
Intervention: Drug: Photofrin photodynamic therapy.
13 Not yet recruiting Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
Condition: Glioma - Recurrent Grade II
Intervention: Biological: GBM6-AD and poly-ICLC
14 Unknown  Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
Conditions: Grade IV Glioma;   Grade IV Astrocytoma;   Glioblastoma Multiforme
Intervention: Biological: TVI-Brain-1
15 Completed Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors
Condition: Glioblastoma
Intervention: Drug: TransMID
16 Completed Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: therapeutic autologous lymphocytes;   Genetic: gene expression analysis;   Other: laboratory biomarker analysis
17 Completed Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
Conditions: Glioma;   High Grade Astrocytoma;   Glioblastoma Multiforme
Intervention: Biological: Cancer vaccine plus immune adjuvant, plus activated white blood cells
18 Terminated Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Diffuse Astrocytoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Recurrent Adult Brain Tumor
Interventions: Drug: erlotinib hydrochloride;   Drug: isotretinoin;   Other: laboratory biomarker analysis;   Genetic: protein expression analysis
19 Enrolling by invitation Proteome-based Personalized Immunotherapy of Glioblastoma
Condition: Glioblastoma
Interventions: Biological: Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes;   Biological: Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
20 Completed Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Conditions: Glioblastoma;   Anaplastic Astrocytoma
Interventions: Drug: AP 12009 10 µM;   Drug: AP 12009 80 µM;   Drug: temozolomide or PCV;   Device: Drug delivery system for administration of AP 12009;   Procedure: Placement of Drug Delivery System

   Previous Page Studies Shown (1-20) Next Page (21-30) Show next page of results    Last Page
Indicates status has not been verified in more than two years